Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

Journal of the National Cancer Institute

Volumn 102, Issue 1, 2010, Pages 47-53

  Eilers, R E ^a   Gandhi, M ^a   Patel, J D ^a   Mulcahy, M F ^a   Agulnik, M ^a   Hensing, T ^b   Lacouture, Mario E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LAPATINIB; PANITUMUMAB;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; DERMATOPHYTE; FEMALE; FISHER EXACT TEST; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOPLASM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; DERMATOMYCOSES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS; PREVALENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SKIN; SKIN DISEASES, BACTERIAL; SKIN DISEASES, INFECTIOUS; SKIN DISEASES, VIRAL; YOUNG ADULT;

EID: 74049120784     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp439     Document Type: Article

References (38)

1. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6 ( 10 ): 803-812.
2. Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008; 6 ( 7 ): 696-706.
3. Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health Syst Pharm. 2007; 64: (9 suppl 5): S15-S24.
4. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16 ( 9 ): 1425-1433.
5. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxic-ities: an evolving paradigm in clinical management. Oncologist. 2007; 12 ( 5 ): 610-621.
6. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007; 23 ( 1 ): 42-45.
7. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007; 72 ( 3-4 ): 152-159.
8. Witherspoon JN, Wagner L, Rademaker A, West DP, Rosenbaum SE, Lacouture ME. Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor induced rash. J Clin Oncol. 2008; 26 (suppl 15S): 9559.
9. Kardaun SH, Van Duinen KF. Erlotinib-induced fl orid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol. 2007; 33 ( 1 ): 46-49.
10. Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer. 2008; 9 ( 1 ): 59-60.
11. Cholongitas E, Kokolakis G, Ioannidou D. How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors ' associated rash? Int J Dermatol. 2008; 47 ( 11 ): 1203-1204.
12. Lord HK, Junor E, Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner Trial. Clin Oncol. 2008; 20 ( 1 ): 96.
13. Lacouture ME, Basti S, Patel J, Benson A III. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006; 4 ( 5 ): 236-238.
14. Pearse AGE. Histochemistry, Theoretical and Applied. 3rd ed. London, UK: Churchill Livingstone; 1968.
15. Braun-Falco M, Schempp W, Weyers W. Molecular diagnosis in der-matopathology: what makes sense, and what doesn't. Exp Dermatol. 2009; 18 ( 1 ): 12-23.
16. SAS Institute Inc. SAS OnlineDoc® 9.2. Cary, NC: SAS Institute Inc; 2007.
17. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001; 144 ( 6 ): 1169-1176.
18. Boeck S, Wollenberg A, Heinemann V. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Ann Oncol. 2007; 18 ( 9 ): 1582-1583.
19. Graham PL III, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006; 144: 318-325.
20. Scope A, Agero AC, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007; 25 ( 34 ): 5390-5396.
21. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008; 113 ( 4 ): 847-853.
22. Lacouture ME, Mitchell EP, Shearer H, et al. Impact of pre-emptive skin toxicity (ST) treatment (tx) on panitumumab (pmab)-related skin toxic-ities and quality of life (QOL) in patients (pts) with metastatic colorectal cancer (mCRC): Results from STEPP. American Society of Clinical Oncology (ASCO) 2009 Gastrointestinal Cancers Symposium. San Francisco, CA. 2009.
23. Abstract 291. http:// www. asco. org / ASCOv2 / Meetings / Abstracts ?& vmvie w = abst-detail-view & confID = 63 & abstractID = 10396. Accessed June 1, 2009.
24. Trilla A, Miro JM. Identifying high risk patients for Staphylococcus au-reus infections: skin and soft tissue infections. J Chemother. 1995; 7 ( suppl 3 ): 37-43.
25. Carney DN, Fossieck BE Jr, Parker RH, Minna JD. Bacteremia due to Staphylococcus aureus in patients with cancer: report on 45 cases in adults and review of the literature. Rev Infect Dis. 1982; 4 ( 1 ): 1-12.
26. Mayhall G. Hospital Epidemiology and Infection Control. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
27. Davis KA, Stewart JJ, Crouch HK, et al. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004; 39: 776-782.
28. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001; 48 ( suppl A ): S9-S14.
29. Tomi SB, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol. 2005; 53 ( 1 ): 67-72.
30. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997; 89 ( 1 ): 32-40.
31. Breuer K, Haussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and infl uence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol. 2002; 147 ( 1 ): 55-61.
32. Bunikowski R, Miekle ME, Skarabis H, et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000; 105 ( 4 ): 814-819.
33. Yokote R, Tokura Y, Furukawa F, Takigawa M. Decreased responsiveness of T cells to toxic shock syndrome toxin-1 in patients with severe psoriasis at active stage. Arch Dermatol Res. 1997; 289 ( 9 ): 547-550.
34. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25 ( 13 ): 1658-1664.
35. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamy-cin and tetracycline resistance methicillin-resistant Staphylococcus aureus pulse-fi eld type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007; 45 ( 4 ): 1350-1352.
36. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and effi cacy data [2007 ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007; 25 ( 18S ) ( suppl ): 4037.
37. Lehmann P, Zheng P, Lavker RM, Kligman AM. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol. 1983; 81 ( 2 ): 169-176.
38. Mitchell E, Lacouture M, Shearer H, et al. A phase II, open-label trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer patients receiving panitumumab + FOLFIRI or irinotecan-only chemotherapy as 2nd-line treatment. In: 10th World Congress on Gastrointestinal Cancer. Barcelona, Spain [abstract 15007]. J Clin Oncol. 2008;26:644s.